Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 18/20 | 0.92 |
| ▸ | KCNJ3 | P48549 | 18/20 | 0.92 |
| ▸ | KCNJ5 | P48544 | 12/20 | 0.92 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234482 | 0.92 | KCNJ6 (0.84) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL4936063 | 0.86 | KCNJ6 (1.00) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13234480 | 0.83 | KCNJ6 (0.76) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL4937639 | 0.83 | KCNJ6 (0.80) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13234630 | 0.82 | KCNJ6 (0.75) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13234637 | 0.82 | CYP3A4 (0.74) | KCNJ6KCNJ3KCNJ5CYP3A4GAA | |
| SCHEMBL4513114 | 0.81 | KCNJ6 (0.72) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13234479 | 0.81 | KCNJ6 (0.83) | KCNJ6KCNJ3KCNJ5PTPN1GAA | |
| SCHEMBL13234484 | 0.80 | KCNJ6 (0.92) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL23203519 | 0.79 | KCNJ6 (0.65) | KCNJ6KCNJ3KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | KCNJ6 3568/4885KCNJ3 3223/4885KCNJ5 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.